Biohaven Ltd. is exploding higher today following the announcement that the FDA has accepted the company's resubmission for Vyglxia, a treatment for spinocerebellar ataxia. Investor enthusiasm is reflected in the heavy trading volume, which has reached 10.293 million shares compared to the stock's daily average of 2.585 million. This regulatory milestone serves as the primary catalyst for the move, driving the stock well above its 50-day moving average.